2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-17459R
    Clopidogrel hydrogen sulfate (Standard) 120202-66-6
    Clopidogrel (hydrogen sulfate) (Standard) is the analytical standard of Clopidogrel (hydrogen sulfate). This product is intended for research and analytical applications. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor.
    Clopidogrel hydrogen sulfate (Standard)
  • HY-17459S
    Clopidogrel-d3 hydrogen sulfate 1217643-68-9 98%
    Clopidogrel-d3 (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor.
    Clopidogrel-d3 hydrogen sulfate
  • HY-17494B
    Timolol hemimaleate 33305-95-2 98%
    Timolol ((S)-L-714,465; MK 950) hemimaleate is a β-blocker available for both topical and systemic administration. Topical Timolol hemimaleate is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol hemimaleate can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect.
    Timolol hemimaleate
  • HY-17494R
    Timolol (Standard) 26839-75-8
    Timolol (Standard) is the analytical standard of Timolol. This product is intended for research and analytical applications. Timolol is a β-blocker available for both topical and systemic administration. Topical Timolol is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect.
    Timolol (Standard)
  • HY-17497S
    Acebutolol-d7 2701782-36-5 98%
    Acebutolol-d7 is a deuterium labeled Acebutolol. Acebutolol is a selective β1 adrenergic receptor antagonist used in the treatment of hypertension, angina pectoris and cardiac arrhythmias.
    Acebutolol-d7
  • HY-17498B
    Atenolol hydrochloride 51706-40-2 98%
    Atenolol hydrochloride is a cardioselective β1-adrenergic receptor blocker, with a Ki of 697 nM at β1-adrenoceptor in guine pig left ventricle membrane. Atenolol hydrochloride can be used for the research of hypertension and angina pectoris.
    Atenolol hydrochloride
  • HY-17502S
    Simvastatin-d11 1002347-74-1 98%
    Simvastatin-d11 is the deuterium labeled Simvastatin. Simvastatin (MK 733) is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM.
    Simvastatin-d11
  • HY-17503C
    Metoprolol fumarate 80274-67-5 98%
    Metoprolol fumarate (CGP 2175C) is an orally active, selective β1-adrenoceptor antagonist. Metoprolol fumarate shows anti-inflammation, antitumor and anti-angiogenic properties.
    Metoprolol fumarate
  • HY-17504C
    (3R,5R)-Rosuvastatin 1094100-06-7 98%
    (3R,5R)-Rosuvastatin is the (3R,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
    (3R,5R)-Rosuvastatin
  • HY-17504D
    (3S,5R)-Rosuvastatin 1242184-42-4 98%
    (3S,5R)-Rosuvastatin is the (3S,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
    (3S,5R)-Rosuvastatin
  • HY-17557R
    Calcium N5-methyltetrahydrofolate (Standard) 26560-38-3
    Calcium N5-methyltetrahydrofolate (Standard) is the analytical standard of Calcium N5-methyltetrahydrofolate. This product is intended for research and analytical applications. 0
    Calcium N5-methyltetrahydrofolate (Standard)
  • HY-176019
    Methylcarbamyl PAF C-8 98%
    Methylcarbamyl PAF C-8 is resistant to the degradation function of platelet-activating factor acetylhydrolase (PAF-AH). It has a half-life of more than 100 minutes in platelet-poor plasma and possesses the activity of inducing platelet aggregation. In NRK-49 cells overexpressing the PAF receptor, Methylcarbamyl PAF C-8 can induce the expression of c-myc and c-fos, and activate mitogen-activated protein kinase (MAPK). Additionally, Methylcarbamyl PAF C-8 can induce cell cycle arrest in the G1 phase. Methylcarbamyl PAF C-8 holds promise for research in the fields of cardiovascular diseases and anti-cancer therapy.
    Methylcarbamyl PAF C-8
  • HY-176021
    U-44069 serinol amide 98%
    U-44069 serinol amide is a derivative of U-44069 (HY-121825). U-44069 serinol amide is a stable analog of the endoperoxide prostaglandin H2 (HY-136500). U-44069 serinol amide is a vasoconstrictor that can induce preglomerular Ca2+ influx.
    U-44069 serinol amide
  • HY-176022
    U-46619 serinol amide 98%
    U-46619 serinol amide is a derivative of U-46619 (HY-108566). U-46619 serinol amide is a stable analog of Thromboxane A2 (HY-113350) (TXA2). U-46619 serinol amide is a potent TXA2 agonist that can induce platelet shape change and aggregation.
    U-46619 serinol amide
  • HY-176041
    Troponin modulator 1 1448792-38-8 98%
    Troponin modulator 1 (compound 7) modulates the mutant cardiac muscle thin filament function. Troponin modulator 1 enhances Ca2+ sensitivity by phosphorylation with an EC50 of 67 μM .
    Troponin modulator 1
  • HY-176060
    Platelet aggregation-IN-3 1029802-21-8 98%
    Platelet aggregation-IN-3 (Compound 5) is a ligand for H2 histamine receptors, α2(A,C)-adrenergic receptors (α2-AR), and 5-HT2(B,C) serotonin receptors. Platelet aggregation-IN-3 can inhibit platelet aggregation induced by ADP and collagen and can also modulate tumour cell-induced platelet aggregation (TCIPA). Platelet aggregation-IN-3 is promising for research of antiplatelet therapy in cardiovascular diseases and the prevention of cancer-related thrombosis and tumour metastasis.
    Platelet aggregation-IN-3
  • HY-176143
    P2Y1/P2Y6 antagonist 1 98%
    P2Y1/P2Y6 antagonist 1 (Compound 3h) is an indolesulfonylhydrazide derivative. P2Y1/P2Y6 antagonist 1 is an orally active tP2Y1 and rP2Y6 antagonist (IC50 of 9.72 and 1.89 μM, respectively). P2Y1/P2Y6 antagonist 1 can be used in the study of neurological diseases, inflammation, cardiovascular diseases and cancer.
    P2Y1/P2Y6 antagonist 1
  • HY-176215
    RXFP1 receptor agonist-10 2924450-63-3
    RXFP1 receptor agonist-10 (Compound 188) is a RXFP1 receptor agonist (EC50: 0.5 nM). RXFP1 receptor agonist-10 can be used for research of heart failure.
    RXFP1 receptor agonist-10
  • HY-17621S
    Sparsentan-d5 1801597-09-0 98%
    Sparsentan-d5 is deuterium labeled Sparsentan. Sparsentan (RE-021) is a highly potent dual angiotensin II and endothelin A receptor antagonist with Kis of 0.8 and 9.3 nM, respectively.
    Sparsentan-d5
  • HY-176480
    CYP11B2-IN-3 3072732-90-9
    CYP11B2-IN-3 (compound 32) is an orally active and selective CYP11B2 inhibitor with IC50 values of 12.92 nM and 2341 nM for CYP11B2 and CYP11B1, respectively. CYP11B2-IN-3 can be used for study of hypertension.
    CYP11B2-IN-3
Cat. No. Product Name / Synonyms Application Reactivity